IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this paper

Updated cost-effectiveness analysis of trastuzumab for early breast cancer:A UK perspective considering long-term toxicity and pattern of recurrence

Listed author(s):
  • Peter Hall


    (Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds)

  • Claire Hulme

    (Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds)

  • Christopher McCabe

    (Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds)

  • Yemi Oluboyede

    (Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds)

  • Jeff Round

    (Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds)

  • David A Cameron

    (Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds)

Background: Trastuzumab has significantly improved survival outcomes for women with HER2 positive early breast cancer. Trastuzumab was established as a costeffective adjuvant treatment in 2006. We present an updated cost-effectiveness analysis from the UK perspective which explores assumptions about the duration of benefit from treatment, pattern of metastatic recurrence and long-term cardiac toxicity. Methods: A cost-utility analysis was performed using a discrete-state timedependent semi-Markov model to calculate expected costs and benefits over the lifetime of an average cohort of women with HER2 positive early breast cancer treated with or without one year of adjuvant trastuzumab sequentially after chemotherapy. The perspective was the UK NHS. Probabilistic sensitivity analysis is used to characterise uncertainly around expected outcomes. Value of information analysis is used to identify areas of priority for further research. Results: The cost-effectiveness estimates are highly sensitive to the estimated duration of treatment benefit. Trastuzumab remains the cost-effective treatment strategy at a willingness-to-pay threshold of £30,000 per QALY provided the duration of benefit is more than 3.6 years from treatment initiation. An increasing proportion of brain metastases with trastuzumab produces small reductions in the costeffectiveness estimate. Long-term cardiac toxicity must rise to high levels to affect overall life-expectancy and cost-effectiveness. VoI analysis places highest value on research into the duration of treatment benefit. The relationship between progression free survival and overall survival and the costs of cancer recurrence are also important. Conclusion: The use of adjuvant trastuzumab remains cost-effective given current estimates of the duration of treatment effect. Uncertainty around cost-effectiveness could be reduced further by research into the duration of treatment effect, particularly in subgroups where this may be shorter. Long-term follow-up is warranted and methods to accurately measure duration of treatment effect and late toxicities should be developed for future adjuvant drug studies.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL:
File Function: First version, 2010
Download Restriction: This is a non-final version of an article published in PharmacoEconomics May 2011, Volume 29 Issue 5, pages 415-432. The working paper can be downloaded from the web site of the Academic Unit of Health Economics. See 'Note'

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Paper provided by Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds in its series Working Papers with number 1001.

in new window

Length: 28 pages
Date of creation: Jul 2010
Publication status: Published in PharmacoEconomics May 2011, Volume 29 Issue 5, pages 415-432
Handle: RePEc:lee:wpaper:1001
Contact details of provider: Phone: Worsley Building, Level 11, Clarendon Way, LEEDS LS2 9NL
Fax: +44 (0) 113 343 3470
Web page:

More information through EDIRC

No references listed on IDEAS
You can help add them by filling out this form.

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:lee:wpaper:1001. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Judy Wright)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.